

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q77518

Katsuya KISHIKAWA, et al.

Appln. No.: Unassigned

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: September 15, 2003

For: ANTI FIBROTIC AGENT CONTAINING SPHINGOSINE 1-PHOSPHATE  
RECEPTOR AGONIST OR SPHINGOSINE 1-PHOSPHATE AS ACTIVE  
INGREDIENT

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which are all the references of record in parent application No. 10/030,314. Applicant is not submitting duplicate copies of these references but requests that they be listed on the face of any patent granted on the above application. (See 37 CFR §1.98(d)). Copies of any cited copending applications, if not previously submitted, are being submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise

INFORMATION DISCLOSURE STATEMENT  
Continuation of U.S. Appln. No. 10/030,314 (*Q77518*)

remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

 *Susan J. Mack* *DREW HISSONG*  
Susan J. Mack *#44,965*  
Registration No. 30,951

SUGHRIE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
**23373**  
CUSTOMER NUMBER

Date: September 15, 2003

Substitute for Form 1449 A & B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>			
Application Number	Unassigned		
Confirmation Number	Not Yet Assigned		
Filing Date	September 15, 2003		
First Named Inventor	Katsuuya KISHIKAWA		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Sheet	1	of	1
		Attorney Docket Number	Q77518

**U.S. PATENT DOCUMENTS**

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number		
	US 5,260,288	A	11-09-1993	Igarashi et al.
	US 5,374,616	A	12-20-1994	Spiegel et al.
	US 5,712,262	A	01-27-1998	Spiegel
	US 5,663,404	A	09-02-1997	Igarashi et al.
	US 5,627,171	A	05-06-1997	Park et al.
	US 6,210,976	A	04-03-2001	Sabbadini
	US 5,877,167	A	03-02-1999	Igarashi et al.
	US 5,583,160	A	12-10-1996	Igarashi et al.
	US			

---

**FOREIGN PATENT DOCUMENTS**

---

## **NON-PATENT LITERATURE DOCUMENTS**

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation*
		C. GALLOIS et al., Endothelin-1 Stimulates Sphingosine Kinase in Human Hepatic Stellate Cells. A Novel Role for Sphingosine-1-P as a Mediator of Growth Inhibition, Annals of the New York Academy of Sciences, (2000) Vol. 905, pp. 311-314	
		James R. VAN BROCKLYN, Dual Actions of Sphingosine-1-Phosphate: Extracellular Through the G <sub>i</sub> -coupled Receptor Edg-1 and Intracellular to Regulate Proliferation and Survival, The Journal of Cell Biology, (1998) Vol. 142, No. 1, pp. 229-240	
		Ariane MALLAT et al., Growth Inhibitory Properties of Endothelin-1 in Activated Human Hepatic Stellate Cells: A Cyclic Adenosine Monophosphate-mediated Pathway, Journal of Clinical Investigations, (1996) Vol. 98, No. 12, pp. 2770-2778	

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>3</sup> Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to indicate here if English is the language of the application. <sup>8</sup> Translation is attached.